An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia

Abstract

Fig. 1. Overall survival (OS) of AML patients unsuitable for intensive chemotherapy. Patients receiving non-IC had a superior survival compared to those receiving Supportive Care (A). Despite absence of HI, more patients receiving non-IC were alive at 90 days than those on Supportive Care (B).